Published in Cancer Immunol Res on May 26, 2015
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem (2015) 0.87
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res (2016) 0.81
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology (2016) 0.81
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget (2016) 0.80
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep (2016) 0.77
Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Arch (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol (2011) 5.11
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol (2011) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res (2012) 2.39
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol (2014) 1.90
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res (2013) 1.70
PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol (2014) 1.58
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest (2014) 1.34
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother (2008) 1.31
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov (2014) 1.26
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn (2014) 1.21
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov (2014) 1.21
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer (2014) 1.06
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia (2013) 1.05
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol (2014) 0.97
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma (2011) 0.85
Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia. Leuk Lymphoma (2015) 0.81
Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. PLoS One (2014) 0.79
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov (2014) 2.09
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res (2015) 1.08
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol (2016) 1.01
Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res (2016) 0.75
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next Generation Sequencing. J Mol Diagn (2016) 0.75